BioMarin Pharmaceutical (BMRN) reported Wednesday that its trial for Palynziq in adolescents with phenylketonuria showed a significant reduction in blood phenylalanine levels in patients aged 12 to 17.
The study met its primary efficacy endpoint, demonstrating that Palynziq was more effective than diet alone in lowering blood Phe levels. The safety results were consistent with the known profile of the medicine.
The company plans to present detailed findings at an upcoming medical meeting and will seek regulatory approval later this year to expand Palynziq's label for adolescent use.
Price: 68.00, Change: +0.06, Percent Change: +0.09
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。